Alto Neuroscience, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Alto Neuroscience is a clinical-stage biopharmaceutical company developing personalized psychiatric treatments using its Precision Psychiatry Platform, which analyzes neurocognitive, EEG and wearable-device data to identify biomarkers and treatment-responsive patient populations. The company reported unaudited results for the three months ended March 31, 2024. Its pipeline includes five clinical-stage assets targeting major depressive disorder and schizophrenia. Common stock trades on the NYSE under ANRO.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $10.0 million | $5.6 million | +$4.3 million |
| General and administrative expense | $4.4 million | $1.6 million | +$2.8 million |
| Total operating expenses | $14.4 million | $7.2 million | +$7.2 million |
| Loss from operations | $(14.4) million | $(7.2) million | Higher loss |
| Other income, net | $1.0 million | $(0.1) million | +$1.1 million |
| Net loss | $(13.4) million | $(7.3) million | Loss increased $6.1 million |
| Net loss per share | $(0.76) | $(1.97) | Improved due to higher share count |
| Net cash used in operating activities | $(11.0) million | $(7.5) million | Cash use increased $3.5 million |
There is no meaningful gross or net profit margin because Alto has no product revenue and remains loss-making. Stock-based compensation was $2.2 million, compared with $0.5 million in Q1 2023, and represented a significant non-cash component of operating expenses.
- Cash and cash equivalents were $205.9 million at March 31, 2024, compared with $82.5 million at December 31, 2023.
- Net cash provided by financing activities was $134.6 million, primarily from the February 2024 IPO.
- The IPO issued 9,246,000 shares at $16.00 per share and generated approximately $132.9 million of net proceeds after underwriting discounts and offering expenses.
- Accumulated deficit was $90.4 million at March 31, 2024.
- Term loan liabilities totaled approximately $10.0 million net of discounts and costs, including $1.1 million classified as current and $8.8 million as non-current. The loan matures December 1, 2026.
- Management stated that existing cash and cash equivalents are expected to fund operating expenses and capital expenditures into 2027, but also expects to require substantial additional capital to complete development.
Material changes versus the prior comparable period
- Research and development expense increased primarily because of ongoing Phase 2b trials for ALTO-100 and ALTO-300 and higher personnel-related costs.
- General and administrative expense increased because of higher personnel costs, including stock compensation, and professional fees associated with operating as a public company.
- Interest income increased by $1.3 million because of substantially larger cash balances invested in money market funds.
- Operating cash use increased as the company expanded clinical activities and prepaid insurance and other costs.
- The February IPO converted all outstanding preferred stock into 13,664,261 shares of common stock. Preferred stock and the related preferred-stock warrant liability were eliminated or reclassified to equity.
- Shares outstanding increased from approximately 3.8 million at December 31, 2023 to approximately 26.9 million at March 31, 2024, reflecting the preferred-stock conversion, IPO and other equity activity.
- In January 2024, the company implemented a 1-for-2.2241 reverse stock split; presented share and per-share amounts were retrospectively adjusted.
Guidance, outlook, commentary and risks
- Alto expects operating losses and negative operating cash flows to continue and expects research and development spending to increase as clinical programs advance.
- Topline data are expected from the ALTO-100 Phase 2b trial in the second half of 2024, from the ALTO-300 Phase 2b trial in the first half of 2025, and from the ALTO-203 proof-of-concept trial in the first half of 2025.
- The company planned to initiate an ALTO-101 Phase 2 proof-of-concept trial in the first half of 2024 and expected a June 18, 2024 FDA Type C meeting regarding ALTO-100 and its biomarker approach.
- In April 2024, Alto reported positive Phase 1 results for a transdermal ALTO-101 formulation, including higher plasma exposure and a more favorable tolerability profile than oral administration. This is a subsequent event, not a Q1 operating result.
- The April ALTO-101 milestone under the MedRx agreement requires a $0.75 million cash payment and issuance of 46,875 common shares during Q2 2024.
- Key risks include clinical trial failure or delay, difficulty enrolling biomarker-selected patients, uncertain FDA acceptance of the biomarker and companion-diagnostic strategy, safety or tolerability issues, manufacturing and supply-chain dependence, competition, intellectual-property challenges, and the need for additional financing.
- The loan agreement is secured by substantially all assets other than intellectual property, restricts certain activities, and permits the lender to convert up to $4.0 million of outstanding debt into common stock. Additional debt or equity financing could further dilute stockholders.
- Potential contingent payments under license and asset-purchase agreements include development, regulatory and sales milestones and royalties. No significant litigation was pending or threatened as of March 31, 2024.
- Management concluded that disclosure controls and procedures were effective at the reasonable assurance level, with no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Cash runway: Verify whether the projected funding period through 2027 remains reasonable after updated trial timelines, spending levels and the Q2 2024 ALTO-101 milestone.
- Clinical execution: Track enrollment, trial conduct and topline results for ALTO-100, ALTO-300, ALTO-203 and ALTO-101.
- Regulatory strategy: Confirm FDA feedback on the biomarker-based development approach and any companion-diagnostic requirements.
- Capital needs: Assess the timing, size and terms of future financing and the resulting dilution or additional debt restrictions.
- Debt exposure: Review repayment obligations, interest rates, covenant compliance, collateral and the lender’s equity-conversion rights.
- License economics: Quantify potential milestone, royalty and sublicense obligations as programs advance.
- Intellectual property: Verify patent expiration and exclusivity timelines, particularly for ALTO-100, ALTO-202 and ALTO-203.
- Post-IPO ownership and liquidity: Monitor lock-up expirations, registration rights, option issuances and potential share sales that may affect the stock price.